2022. Systems approach to NAD+ restoration via NNMT inhibition
Ongoing Monitoring and Evaluation We will monitor your progress on a weekly basis, making any necessary adjustments to ensure effectiveness
Because AOD 9604 has not completed the full clinical development pathway, its comprehensive side-effect profile in humans is not well characterised and should not be assumed to be benign
Still, it is worth being aware of the possibilities, especially if you have certain pre-existing conditions
Every batch is third-party tested to 99% purity by HPLC, with a certificate of analysis (COA) available on request
At Southeastern Recovery Center, we understand the challenges of navigating insurance policies, especially during the stressful time of seeking addiction treatment